Johnson & Johnson (BVMF:JNJB34)

Market Cap	3.02T +44.4%
Revenue (ttm)	521.60B +6.0%
Net Income	148.43B +90.6%
EPS	61.08 +90.5%
Shares Out	n/a
PE Ratio	20.33
Forward PE	20.59
Dividend	1.26 (1.50%)
Ex-Dividend Date	Nov 25, 2025

Volume	95,312
Average Volume	10,535
Open	81.59
Previous Close	83.26
Day's Range	81.59 - 83.83
52-Week Range	54.62 - 84.18
Beta	0.35
RSI	75.91
Earnings Date	Jan 21, 2026

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1886
• Employees: 138,100
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: JNJB34

Financial Performance

In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.

Financial numbers in USD